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Background: A prolonged corrected QT (QTc) interval is a marker for an increased risk of sudden cardiac death. Prior studies have shown that 
while testosterone and progesterone shorten the action potential, estrogen lengthens the QTc interval. We evaluated the relationship between oral 
contraceptive (OC) use, type of OC, and QTc interval in a managed care population.
Methods: We retrospectively identified 410,782 12-lead surface ECGs performed at Northern California Kaiser Permanente on female patients 
between 15-53 years as part of clinical care from January, 1995 to June, 2008. Machine-read raw QT was corrected for heart rate using log-
linear regression. OC generation (first, second and third) was classified by increasing progestin androgenic potency, while the fourth generation 
was classified as anti-androgenic. Statistical analysis was performed using multivariable linear regression adjusting for age, race, smoking and 
comorbidity.
Results: Among 410,782 women, 8.4% were on OC. Women taking OC were younger (33.2 vs 40.7 years) and had less comorbidity than unexposed 
women (p<0.0001). Overall, exposed women had a shorter QTc (400.8 msec) than unexposed women (403.5 msec) (p<0.0001). In multivariate 
analysis, there was an independent shortening effect of OCs overall (slope = -0.5ms; SE = 0.12, p<0.0002). When examined by OC generation, users 
of first and second generation progestins had a significantly shorter QTc than non-users (first generation: slope = -1.0ms, SE = 0.18, p<0.0001; 
second generation: slope = -2.0ms, SE = 0.23, p<0.0001) while users of fourth generation had a significantly longer QTc than non-users (slope = 
3.6ms, SE = 0.35, p<0.0001).
Conclusion: Overall, OC use has a small but significant shortening effect on the QTc. OC generation is an important predictor of QTc length 
after adjusting for age and comorbidity, with shorter QTc seen with first and second generation OC. Fourth generation OC use with anti-androgenic 
progestin has a lengthening effect on the QTc. As even small QTc prolongation can be clinically relevant, particularly when combined with other 
factors and QTc prolonging medications, careful examination of adverse event rates in fourth generation OC users is needed.
